Answers are grounded in this paper and cite their sources.
Purpose of Investigation: The study was performed to evaluate four years of experience (2012-2015) in high risk-human papillomavirus (hr-HPV) testing in the cervical cancer screening in Latina (Italy). Materials and Methods: The hr-HPV as primary test is performed only on women aged 35-64, followed by a Pap test as triage, while women aged 25-34 are invited to perform only a Pap test. Results: Women resulted positive to hr-HPV test and positive to Pap test were 5.6% and 4.1%, respectively. Among women aged 25-34, the hr-HPV test was used as triage for women with atypical squamous cells of undetermined significance (ASCUS) and 69.9% resulted positive to the test. The positive predictive value (PPV) for high cervical intraepithelial lesions (HSIL) was higher in women aged 35-64 (9.9% vs. 6.9%), while the detection rate (DR) for HSIL was higher in young women (2.4‰ vs. 1.2‰). The authors found that 52.5% of women with hr-HPV+/Pap test resulted with hr-HPV+ at one-year recall and the DR for HSIL lesions of this population was very low (0.27‰). Discussion: The present data confirms that the application of hr-HPV test showed elevated performance in cervical cancer screening and that the application of hr-HPV test in managing ASCUS leads to a decreased use of inappropriate colposcopies. Finally, it may be useful to extend the period of follow-up for women hr-HPV+/Pap test to reduce unnecessary colposcopies.
No takes yet. Share an insight, caveat, or question.
Chiappetta et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: